In a groundbreaking collaboration, Kiora Pharmaceuticals and Senju Pharmaceutical have joined forces to propel the development of KIO-301, a potential therapeutic for retinal diseases. The partnership, which covers key Asian marketplaces including Japan and China, is a bold stride towards addressing the unmet medical needs of retinal patients in the region, underscoring both companies’ dedication to enhancing healthcare outcomes.
This partnership not only signifies the union of two pharmaceutical giants but also entails a robust financial arrangement, including a substantial upfront payment and potential milestone payments that could add up to an impressive $285 million. Royalties on net sales are set to augment this significant investment, a clear indicator of the high stakes and expectations surrounding this venture.
Under the terms of this agreement, Senju Pharmaceutical has been granted an exclusive option to initiate a development and commercialization agreement for KIO-301. This option becomes exercisable after the reporting of topline data from the ongoing ABACUS-2 phase 2 clinical trial. This strategic setup permits Senju to team up with Théa Open Innovation, Kiora’s exclusive global development and commercialization partner for KIO-301 outside of Asia.
Earlier in 2024, Kiora had entered into a worldwide agreement with Théa Open Innovation, a sister company of the renowned ophthalmic specialty company, Laboratoires Théa. This agreement, which saw Kiora receive a $16 million upfront payment, also promises Kiora up to $285 million upon hitting specific clinical development, regulatory, and commercial milestones. Moreover, Kiora stands to receive tiered royalties of up to a low 20% on net sales and reimbursement of KIO-301 research and development expenses.
The partnership between Kiora and Senju Pharmaceutical is a testament to the evolving landscape of biotechnology, where collaborations are increasingly becoming the norm for expediting pharmaceutical innovation. The key terms and conditions of this exclusive development and commercialization agreement have been agreed to, subject to Senju exercising its option. With the agreement, Senju would shoulder all development, regulatory, and commercial activities in the licensed territory.
Shuhei Yoshida, president of Senju, has lauded the partnership, expressing optimism about the potential of KIO-301. He noted, “Like elsewhere in the world, patients in Asia with inherited retinal diseases, including retinitis pigmentosa, have no therapeutic options to slow their disease progression nor restore what has already been lost. KIO-301 is a very promising, novel therapeutic with the potential to give vision back to affected individuals.”
The fusion of Kiora’s innovative prowess and Senju’s robust market presence in Asia could result in a paradigm shift in treating retinal diseases. The venture promises to illuminate the path for similar partnerships aimed at advancing pharmaceutical innovation and meeting unmet medical needs across the globe.
Read more from ophthalmologytimes.com
